Lastly, our study exclusively included patients receiving pembrolizumab‐based therapies, and the incidence, timing, and outcomes of AKI may differ with other FDA‐approved immunotherapy regimens, such as dual checkpoint blockade oranti‐PD‐L1 monoclonal antibodies. This evidence concerns the gene CD274 and acute kidney injury.